Annual report


From our Chair of the Board and Executive Director

2019 in numbers


new chemical entities in DNDi’s R&D pipeline


clinical trials at 59 sites in 20 countries


patients in active DNDi clinical studies

Responding to COVID-19

We can’t look back on our progress in 2019 without acknowledging the unprecedented challenges we face today. In the face of the global pandemic, our teams are working to accelerate research to protect the most vulnerable.

Read the story

The urgency of innovation

The last decade has seen remarkable progress against neglected tropical diseases. What will it take to secure and sustain new gains in the decade to come? Bringing the best science for the most neglected is more important than ever.

Read the story

Prioritizing paediatric R&D

We’ve developed four child-friendly treatments that have saved millions of lives. With new treatments in the R&D pipeline, we’re working to ensure more vulnerable children can benefit from the fruits of scientific progress.

Read the story

Globally networked to conduct research where it's needed most

18 clinical studies for 6 diseases, at 59 sites in 20 countries

Sleeping sickness:
the last mile challenge

The development of fexinidazole – the first safe, effective, all-oral treatment for sleeping sickness – required tremendous cooperation and determination to enable world-class clinical research in some of the most remote African communities. Our African partners are now driving efforts to ensure widespread patient access to the game-changing drug for all patients in need.

Strengthening capacity in 2019

Diseases & projects

No one should suffer from lack of treatment because their disease can’t turn a profit

Sleeping sickness

Making medical history with revolutionary treatments

Read more

Visceral leishmaniasis

Partnering for a new generation of treatments

Read more

Cutaneous leishmaniasis

Confronting a disfiguring and stigmatizing disease

Read more

Chagas disease

Progress towards better treatments to stop a silent killer

Read more

Filaria: River blindness

Developing a rapid cure for a devastating illness

Read more


Looking for alternatives to amputation

Read more


A strawberry-flavoured treatment to save children’s lives

Read more

Hepatitis C

Millions still waiting for a cure

Read more

New hope to stop a silent killer

Shorter, safer treatments are urgently needed for millions of people affected by Chagas disease. Current treatment is effective but lasts eight weeks and sometimes has serious side effects. Our study in Bolivia showed treatment could be reduced to just two weeks – and be just as effective.

2019 R&D highlights

We’ve built a robust portfolio of 46 R&D projects, including 23 entirely new compounds in testing – with several progressing to the next stage of development in 2019.

This progress would not be possible without the essential contributions of our global network of R&D partners.

Read the R&D highlights of 2019

Read our full 2019 R&D Programmes in Review

2019 financial information

DNDi goes beyond the required audited financial statements in providing additional key financial performance indicators on expenditures and contributions.

Read our 2019 Financial and Performance Report

A word of thanks

DNDi has now delivered eight new treatments for neglected patients and aims to deliver another eight to ten, for a total of 16-18 new treatments by 2023. We are deeply grateful for the support of all our donors and partners, and for their commitment and collaboration since 2003.

Read the list of donors

Read the list of main R&D partners

How your donations are used

All contributions large and small have helped advance DNDi’s mission and goals.


Social mission: R&D, strengthening capacity, and advocacy


General management



Photo credits (from top): Karin Schermbrucker-Unicef/DNDi; Vinicius Berger-DNDi; Emmanuel Museruka-DNDi; Maneesh Agnihotri-DNDi; Xavier Vahed-DNDi; Graham Crouch-DNDi; Emmanuel Museruka-DNDi; Kenny Mbala-DNDi; Maneesh Agnihotri-DNDi; Fábio Nascimento-DNDi; Felipe Abondano-DNDi; Neil Brandvold-DNDi; Abraham Ali-DNDi; Karin Schermbrucker-Unicef/DNDi; DNDi; Lameck Ododo-DNDi